Share This Author
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies.
WHO-EORTC classification for cutaneous lymphomas.
The characteristic features of the different primary cutaneous lymphomas and other hematologic neoplasms frequently presenting in the skin are described, and differences with the previous classification schemes are discussed.
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
In summary, immunostains can be used to determine the GCB and non-GCB subtypes of DLBCL and predict survival similar to the cDNA microarray.
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Findings establish chronic active BCR signalling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.
Stromal gene signatures in large-B-cell lymphomas.
Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment, and a multivariate model created from three gene-expression signatures predicted survival both in patients who received CHOP and patients who receive R-CHOP.
Oncogenically active MYD88 mutations in human lymphoma
The dependence of ABC DLBCLs on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signalling, is described and the development of inhibitors of IRAK4 kinase and other components of this pathway for the treatment of tumours bearing oncogenic MyD88 mutations are supported.
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
- A. Rosenwald, George W. Wright, L. Staudt
- Medicine, BiologyThe New England journal of medicine
- 20 June 2002
DNA microarrays can be used to formulate a molecular predictor of survival after chemotherapy for diffuse large-B-cell lymphoma and this gene-based predictor and the international prognostic index were independent prognostic indicators.
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.
The criteria and significance of early or precursor lesions and the identification of certain lymphoid neoplasms largely associated with particular age groups, such as children and the elderly are addressed, and the issue of borderline categories having overlapping features with large B-cell lymphomas is reviewed.